Novel prodrug approach to photodynamic therapy: Fmoc solid-phase synthesis of a cell permeable peptide incorporating 5-aminolaevulinic acid

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 16, 2007, Pages 4518-4522

  Dixon, Mark J ^a   Bourré, Ludovic ^b   MacRobert, Alexander J ^b   Eggleston, Ian M ^a  

^a University of Bath   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

5 Aminolaevulinic acid; Cell penetrating peptide; Photodynamic therapy; Prodrug; Solid phase peptide synthesis

Indexed keywords

AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG SYNTHESIS; NONHUMAN; PHOTODYNAMIC THERAPY; SOLID PHASE SYNTHESIS;

AMINOLEVULINIC ACID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MOLECULAR STRUCTURE; PEPTIDES; PERMEABILITY; PHOTOCHEMOTHERAPY; PRODRUGS; PROTOPORPHYRINS; TIME FACTORS;

EID: 34447331718     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.095     Document Type: Article

References (28)

1. Detty M.R., Gibson S.L., and Wagner S.J. J. Med. Chem. 47 (2004) 3897
2. Hamblin M.R., and Hasan T. Photochem. Photobiol. Sci. 5 (2004) 436
3. Berg K., Selbo P.K., Weyergang A., Dietze A., Prasmickaite L., Bonsted A., Engesaeter B.O., Angell-Petersen E., Warloe T., Frandsen N., and Hogset A. J. Microscopy 218 (2005) 133
4. Fotinos N., Campo M.A., Popowycz F., Gurny R., and Lange N. Photochem. Photobiol. 82 (2006) 994
5. Datta S.N., Loh C.S., MacRobert A.J., Whatley S.D., and Matthews P.N. Br. J. Cancer 78 (1998) 1113
6. Lopez R.F.V., Lange N., Guy R., and Bentley M.V.L.B. Adv. Drug Deliv. Rev. 56 (2004) 77
7. Casas A., Batlle A.M.C., Butler A.R., Robertson D., Brown E.H., MacRobert A., and Riley P.A. Br. J. Cancer 80 (1999) 1525
8. Rogers L.M.-A., McGivern P.G., Butler A.R., MacRobert A.J., and Eggleston I.M. Tetrahedron 61 (2005) 6951
9. Berger Y., Greppi A., Siri O., Neier R., and Juillerat-Jeanneret L. J. Med. Chem. 43 (2000) 4738
10. Berger Y., Ingrassia L., Neier R., and Juillerat-Jeanneret L. Bioorg. Med. Chem. 11 (2003) 1343
11. Schneider R., Tirand L., Frochot C., Vanderesse R., Thomas N., Gravier J., Guillemin F., and Barberi-Heyob M. Anti-Cancer Agents Med. Chem. 6 (2006) 469
12. Choi Y., Weissleder R., and Tung C.-H. Cancer Res. 66 (2006) 7225
13. Gadmar O.B., Moan J., Scheie E., Ma L.W., and Peng Q. J. Photochem. Photobiol. 67 (2002) 187
14. Walker I., Vernon D.I., and Brown S.B. Bioorg. Med. Chem. Lett. 14 (2004) 441
15. Tréhin R., and Merkle H.P. Eur. J. Pharm. Biopharm. 58 (2004) 209
16. Cyclosporin:. Rothbard J.B., Garlington S., Lin Q., Kirschberg T., Kreider E., McGrane P.L., Wender P.A., and Khavari P.A. Medicine 6 (2000) 1253
17. Doxorubicin:. Rousselle C., Smirnova M., Clair P., Lefauconnier J.M., Chavanieu A., Calas B., Scherrmann J.M., and Temsamani J. J. Pharmacol. Exp. Ther. 296 (2001) 124
18. Taxol:. Kirschberg T.A., Van Deusen C.L., Rothbard J.B., Yang M., and Wender P.A. Org. Lett. 5 (2003) 3459
19. Fischer P.M., Zhelev N.Z., Wang S., Melville J.E., Fahraeus R., and Lane D.P. J. Pept. Res. 55 (2000) 163
20. R = 11.69 min. Compound 2 (285 mg, 0.13 mmol) was dissolved in TFA/thioanisole/water/DCM (16:2:1:1, 10 mL) and stirred at room temperature for 2 h. The solvent was removed in vacuo and the resulting residue partitioned between water (20 mL) and Et...
21. Fischer P.M. J. Peptide Sci. 9 (2003) 9
22. Coste J., Le Nguyen D., and Castro B. Tetrahedron Lett. 31 (1990) 205
23. The solid phase synthesis of a 2-ALA derivative has been reported-see. Marcaurelle L.A., and Bertozzi C.R. Tetrahedron Lett. 39 (1998) 7279
24. Battah S., Balaratnam S., Casas A., O'Neill S., Edwards C., Batlle A., Dobbin P., and MacRobert A.J. Mol. Cancer Ther. 6 (2007) 876
25. 4 cells per well. After 48 h, the culture medium was removed, and the wells were washed with PBS. The cells were incubated with freshly prepared solutions of 3 at 0.005, 0.01, 0.05, 0.01, and 0.5 mM. Serum-free medium (100 μL) containing varying prodrug concentrations was added to a designated series of wells. Each plate contained control wells with cells, but without added drug for determination of the background reading, and reference wells containing cells incubated with the same ALA concentrations. Fluorescence readings were taken at 4, 5, 7, 24, and 48 h after addition of 3, and the plates were incubated at 37 °C between measurements. The fluorescence signal from each well was measured using a Perkin-Elmer LS-50B spectrofluorimeter, with excitation at 405 nm and 635 nm emission, with slit widths set to 10 nm and an internal 530 longpass filter used on the emission side. The mean fluorescence was calculated after subtraction of the control values (i.e., without addition of ALA). For temperature studies, PAM212 were seeded in two 96-well plates, as before, and treated with 3 (0.3mM in clear media, 100 μL/well). The plates were wrapped in foil and incubated at 37 and 4 °C, respectively, for 12 h, whereupon the prodrug solution was removed. The cells were rinsed in PBS and clear media (100 μL) were added to each well. Generation of PpIX fluorescence was then monitored as before.
26. Wadia J.S., Stan R.V., and Dowdy S.F. Nat. Med. 10 (2004) 310
27. Jones S.W., Christison R., Bundell K., Voyce C.J., Brockbank S.M.V., Newham P., and Lindsay M.A. Br. J. Pharmacol. 145 (2005) 1093
28. Kaiser E., Colescott R.L., Bossinger C.D., and Cook P.I. Anal. Biochem. 34 (1970) 595